FIELD: medicine.
SUBSTANCE: disclosed is an agent for reducing intraocular pressure, which is a suspension of chitosan-coated calcium phosphate nanoparticles with diameter of 120–150 nm, containing a combination of superoxide dismutase 1 with enzymatic activity 10–30 kU/ml and enalaprilat as an angiotensin converting enzyme inhibitor with concentration 1–5 mM. Also disclosed is a method of treating eye diseases with said agent.
EFFECT: group of inventions provides intensified effect of reducing intraocular pressure with reduced risk of local and general adverse reactions.
5 cl, 3 dwg, 5 tbl, 5 ex
| Title | Year | Author | Number |
|---|---|---|---|
| METHOD OF REDUCING INTRAOCULAR PRESSURE | 2011 |
|
RU2472471C1 |
| AGENT FOR TREATMENT OF EYE DISEASES AND METHOD OF ITS USE | 2016 |
|
RU2657780C2 |
| METHOD OF TREATING EYE DISEASES ACCOMPANIED BY OXIDATIVE STRESS | 2014 |
|
RU2577236C1 |
| PHARMACEUTICAL COMPOSITION FOR LOCAL APPLICATION IN TREATING INFLAMMATORY EYE DISEASES AND METHOD FOR USING IT | 2012 |
|
RU2508123C1 |
| METHOD OF TREATING PROGRESSING HYPERMETROPIC SHIFT AFTER KERATOTOMY IN CASE OF NORMAL INTRAOCULAR PRESSURE | 2016 |
|
RU2612001C1 |
| METHOD FOR SELECTING A METHOD FOR TREATING PATIENTS WITH PRIMARY OPEN-ANGLE GLAUCOMA | 2021 |
|
RU2761048C1 |
| METHOD FOR TREATMENT AND PROPHYLAXIS OF OPHTHALMIC DISEASE ASSOCIATED WITH EYE TISSUE ISCHEMIA | 2004 |
|
RU2268722C2 |
| IMPLANT FOR POSTERIOR POLE REVASCULARISATION IN PATIENTS WITH GLAUCOMA | 2014 |
|
RU2557915C1 |
| METHOD OF NEEDLING FOR CICATRISATION OF FILTERING BLEB AFTER ANTIGLAUCOMA OPERATIONS | 2024 |
|
RU2824290C1 |
| METHOD FOR PREDICTION OF DEVELOPING NEURODEGENERATIVE DISEASES, UNDERLYING THE PATHOGENESIS OF WHICH IS GAMMA-SYNUCLEINOPATHY | 2018 |
|
RU2703430C1 |
